News Image

Despite its growth, NASDAQ:CORT remains within the realm of affordability.

By Mill Chart

Last update: Jan 3, 2024

Uncover the potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that our stock screener found to be reasonably priced. NASDAQ:CORT is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.

Growth Insights: NASDAQ:CORT

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:CORT has received a 7 out of 10:

  • CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.94% yearly.
  • Looking at the last year, CORT shows a quite strong growth in Revenue. The Revenue has grown by 13.20% in the last year.
  • CORT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.35% yearly.
  • The Earnings Per Share is expected to grow by 23.26% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, CORT will show a quite strong growth in Revenue. The Revenue will grow by 15.07% on average per year.
  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

Assessing Valuation Metrics for NASDAQ:CORT

An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:CORT has received a 5 out of 10:

  • 81.68% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 79.70% of the companies listed in the same industry.
  • Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than 79.21% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 86.63% of the companies are valued more expensively.
  • CORT has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as CORT's earnings are expected to grow with 18.68% in the coming years.

Health Examination for NASDAQ:CORT

To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 8 out of 10:

  • CORT has an Altman-Z score of 14.10. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
  • CORT has a better Altman-Z score (14.10) than 90.10% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • CORT has a Current Ratio of 3.54. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • CORT has a Quick Ratio of 3.48. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.

Profitability Insights: NASDAQ:CORT

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:CORT, the assigned 8 is noteworthy for profitability:

  • The Return On Assets of CORT (15.39%) is better than 95.05% of its industry peers.
  • CORT has a Return On Equity of 19.80%. This is amongst the best in the industry. CORT outperforms 91.58% of its industry peers.
  • The Return On Invested Capital of CORT (18.44%) is better than 94.06% of its industry peers.
  • CORT had an Average Return On Invested Capital over the past 3 years of 23.51%. This is significantly above the industry average of 16.81%.
  • The last Return On Invested Capital (18.44%) for CORT is well below the 3 year average (23.51%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
  • The Profit Margin of CORT (20.31%) is better than 94.55% of its industry peers.
  • CORT has a better Operating Margin (21.82%) than 89.60% of its industry peers.
  • CORT has a better Gross Margin (98.64%) than 97.03% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

Check the latest full fundamental report of CORT for a complete fundamental analysis.

Keep in mind

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/23/2024, 1:10:59 PM)

23.725

+1.43 (+6.39%)

CORT News

News Imagea day ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image4 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image8 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image8 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image15 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image22 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image22 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
News Image2 months ago - Corcept Therapeutics IncorporatedCorcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

CORT Links
Follow us for more